Abstract Prostate cancer is a major public health problem in developed countries. The remarkable biological and clinical heterogeneity of prostate cancer provides unique opportunities as well as challenges for the diagnostic imaging evaluation of this prevalent disease. The disease is characterized by a natural history that ranges from localized slowly growing hormone-dependent tumor progressing to metastatic hormone-refractory disease. PET is an ideal imaging tool for noninvasive interrogation of the underlying tumor biology.
Introduction
Prostate cancer is the most common male cancer with about 1 in 6 men in industrial countries developing the cancer in their lifetime. During the period 2005-2009, the ageadjusted incidence rate and death rate were 154.8 per 100,000 men per year and 23.6 per 100,000 men per year, respectively, in the US [1, 2] . In the era since the introduction of prostate specific antigen (PSA) screening, the stage distribution for all races during the period 2000-2008 was 81 % localized (primary tumor confined to the prostate gland), 12 % regional (spread to regional lymph nodes), 4 % distant (metastases to other organs), and 3 % unstaged [1] . While men with localized prostate cancer are treated with curative intent, approximately 40 % of patients will experience a detectable rise in the serum PSA level (biochemical failure) within 10 years from primary treatment [3] . Locally recurrent cancer is eventually detected in about 25-35 %, metastatic disease only in about 20-25 % and both local recurrence and metastatic disease in 45-55 % of men with biochemical failure [4] . While most men with metastatic disease respond to androgen deprivation therapy, many will develop castrate resistance within 1-3 years with the hallmark of tumor growth despite castrate levels of serum androgens [5, 6] . Castration-resistant metastatic prostate cancer is incurable and the main cause of disease-related morbidity and mortality [7] .
PET is a quantitative tool for noninvasive imaging interrogation of the underlying tumor biology. Several promising radiotracers are currently being investigated for the imaging evaluation of prostate cancer including, but not limited to, 18 F-or 11 C-choline, 18 F-or 11 C-acetate, 16β-18 F-fluoro-5α-dihydrotestosterone, targeted to the androgen receptor, anti-1-amino-3-18 F-fluorocyclobutane-1-carboxylic acid, a synthetic L-leucine analog, as well as PET radiotracers based on prostate-specific membrane antigen, prostate stem cell antigen, and gastrin-releasing peptide receptor [8, 9] . However, the exact diagnostic and prognostic roles of these radiotracers in prostate cancer are undefined and require additional investigation. 18 F-Fluorodeoxyglucose (FDG) is the most common PET radiotracer used for oncological applications. This article briefly reviews the utility and limitations of FDG PET/CT in prostate cancer.
Preclinical studies
The Warburg effect of elevated glucose metabolism in malignant tissue in comparison to normal tissue is the underlying mechanism for the accumulation of FDG in malignant tissue. While the biological detail of this hallmark of cancer is relatively complex, the malignancy-induced hypermetabolism is generally based upon overexpression of cellular membrane glucose transporters (mainly GLUT-1) and enhanced hexokinase enzymatic activity in tumors [10, 11] . In-vitro studies have shown that GLUT1 expression is higher in the poorly differentiated cell lines DU145 and PC-3 than in the welldifferentiated hormone-sensitive LNCaP cell line, suggesting that the level of GLUT1 expression increases with progression of malignancy grade [12] . GLUT1 gene expression is also significantly higher in prostate cancer than in benign prostatic hyperplasia (BPH) tissue and is correlated directly with Gleason score (R=0.274, P=0.026) [13] .
Other studies have shown that androgen may affect the level of FDG uptake in androgen-sensitive, androgen receptor-positive prostate cell lines (e.g. LNCaP, CWR-22) while no effect is noted in androgen-independent, androgen receptor-negative cell lines (e.g. PC-3) [14, 15] . This observation may be due to the modulatory effect of androgens on the GLUT1 and hexokinase expression levels [16, 17] . Kukuk [18] . Androgen ablation therapy reduced the Ki67 proliferation index from 60 % to 3 %, thymidine kinase 1 expression from 32 % to 1 % and the expression of GLUT1 from a baseline level to none. These findings support the notion that androgen has a significant effect on the biology of hormone-sensitive prostate tumors that may then be assessed noninvasively through molecular imaging.
Diagnosis of primary tumor and initial staging
The level of FDG accumulation can overlap in normal prostate, BPH and prostate cancer tissues, which often coexist [19, 20] . A recent investigation assessed the level of FDG uptake in the presumed "normal" prostate gland in relation to age and prostate size in 145 men without known or suspected prostate pathology [21] . The mean and maximum standardized uptake values (SUVs) for the prostate gland were 1.3±0.4 (range 0.1-2.7) and 1.6±0.4 (range 1.1-3.7), respectively, excluding those prostate glands with visible calcification or urethral urine activity. The mean SUV tended to decrease as the prostate size increased (r=−0.16, P=0.058), whereas the prostate size tended to increase with increasing age (r=0.32, P<0.001).
Minamimoto et al. evaluated FDG PET/CT for detecting prostate cancer in 50 men with elevated serum PSA levels who underwent subsequent prostate biopsy [22] . The sensitivity and specificity were 51.9 % and 75.7 % for the entire prostate gland, 73 % and 64 % for the peripheral zone, and 22.7 % and 85.9 % for the central zone, respectively. The positive predictive value of FDG PET/CT was 87 % in a subset of men older than 70 years and with serum PSA level greater than 12 ng/mL. The authors concluded that FDG PET/CT may be useful for detection of peripheral zone prostate cancer in men at more than intermediate risk. Nevertheless, as shown by the same group of investigators in a review of the Japanese nationwide survey of the FDG PET cancer screening program in asymptomatic individuals without a known history of cancer during 2006-2009, PET demonstrated a low sensitivity of only 37 % for detection of prostate cancer [23] .
In another retrospective study that compared FDG, 11 Ccholine, and MRI in patients with suspected prostate cancer, sensitivity for detection of tumor was significantly higher with MRI (88 %) and 11 C-choline PET (73 %) than with FDG PET (31 %) [24] . Recently, Hwang et al. reported incidental prostate hypermetabolism in 1.5 % of patients who had undergone FDG PET/CT for a variety of indications excluding those with known prostate cancer or recent prostate procedures [25] . The validation was through follow-up evaluation with digital rectal examination, serum PSA levels, or biopsy in 65 % of these patients. The median serum PSA levels were 3.2 and 49.7 ng/mL in the benign and cancer groups, respectively. There was no significant difference in the mean SUVmax between the cancer and the benign groups (5.7±5.1 versus 4.8±2.7, P=0.37). The majority of patients with hypermetabolic prostate cancer (56.5 %) had Gleason scores in the range 8-10. There are few data on the use of FDG PET/CT in initial staging of prostate cancer given the general low avidity of FDG for primary prostate cancer. It is interesting, however, that in the early analysis of the National Oncologic PET Registry (NOPR) data in the US involving 2,042 scans for initial staging of prostate cancer (the most common cancer type in the initial staging subgroup), FDG PET/CT had an impact on clinical management in 32 % (95 % CI: 30.0-34.1 %) of the patients [26] .
In summary, FDG PET cannot generally be recommended in the diagnosis or staging of clinically organ-confined disease owing to overlap of uptake among normal, benign and tumor tissues and because the high excreted radiotracer in the adjacent urinary bladder may mask lesions in the prostate gland that are located in the vicinity [27] . False-positive results may also occur with prostatitis [28] . FDG PET may, however, be useful in the subset of patients with suspected poorly differentiated primary tumors (Gleason sum score above 7) and higher serum PSA values [29] .
Biochemical recurrence and restaging
Biochemical failure (PSA relapse) is declared when there is an initial serum PSA of 0.2 ng/mL or higher with a second confirmatory PSA rise in prostatectomized patients or when there is a rise by 2 ng/mL or more above the nadir PSA level in men who have undergone primary radiation treatment [30, 31] . Standard imaging (contrastenhanced CT, 99m Tc-based bone scintigraphy, prostate ultrasonography or MRI) is typically employed to localize the disease in order to direct appropriate treatment (salvage surgery or radiation therapy for local recurrence in the prostate bed or systemic therapy for metastatic disease). More recently, radiolabeled choline (with 11 C or 18 F) has been reported to be useful in this clinical setting with a diagnostic performance that generally depends on the serum PSA level [32] .
FDG PET may be useful in detecting disease in a small number of patients in this clinical setting. In one study, FDG PET was performed before pelvic lymph node dissection in 24 patients with biochemical recurrence and a negative pelvis CT scan [33] . The sensitivity, specificity, accuracy, positive predictive value and negative predictive value of FDG PET in detecting metastatic pelvic lymph nodes were 75.0 %, 100 %, 83.3 %, 100 % and 67.7 %, respectively. In another retrospective study of 91 patients with PSA relapse following prostatectomy and validation of tumor presence by biopsy or clinical and imaging follow-up, mean serum PSA levels were reported to be higher in FDG PET-positive patients than in FDG PET-negative patients (9.5±2.2 ng/ml vs. 2.1±3.3 ng/ml) with an overall PET detection rate of 31 % [34] . However, the unique contribution of PET in this study could not be deciphered since some patients had disease evident on standard imaging and therefore the PET detection rate might have been overestimated. FDG PET has also been found to be advantageous over 111 In-capromab pendetide scintigraphy in this clinical setting [35] .
We recently reported our findings of a prospective investigation on the potential utility of FDG PET/CT and 18 F-NaF PET/CT in detection of occult metastases in 37 men with PSA relapse and negative standard imaging studies [36] . FDG PET/CT only was positive in one patient, 18 F-NaF PET/CT only was positive in eight patients, and both were positive in another two patients (Fig. 1) . Our substantially lower detection rate of 8.1 % (3 of 37 patients) for 18 F-FDG PET/CT in the setting of biochemical recurrence is probably more realistic than those found in the prior studies which occasionally employed concurrent positive standard imaging for validation of PET findings, thereby violating the true definition of PSA relapse only condition.
Assessment of treatment response
Preclinical studies have shown that FDG accumulation in androgen-sensitive prostate tumors declines with androgen withdrawal suggesting that FDG PET might be useful for assessing response and potentially for early detection of a castrate-resistant state [14] . In this context, one clinical study showed that FDG uptake in the primary prostate cancer and metastatic sites decreased over a period of 1-5 months after initiation of androgen deprivation therapy [37] . Nevertheless, another study of prostate cancer in rats showed that the global FDG SUV might remain unchanged after chemotherapy with gemcitabine; however, the potential relevance to clinical setting remains to be established [38] . Our preliminary results show that tumor FDG uptake decreases with successful chemohormonal treatment, although imaging findings may be discordant with those of other manifestations of disease including changes in the levels of serum PSA or circulating tumor cells [39] (Fig. 2) . For example, there may be differences in imaging-based assessment based on the response criteria that are employed in the data analysis such as Response Evaluation Criteria In Solid Tumors (RECIST 1.0 and RECIST 1.1), European Organization for Research and Treatment of Cancer (EORTC), or PET Response Criteria in Solid Tumors (PERCIST) [39] . Clearly additional studies are needed to decipher the optimal combination of relevant data that can most accurately reflect the effect of various current and novel therapies.
Prediction of patient outcome
An important unmet clinical need is the objective assessment of the comparative effectiveness of various conventional and emerging novel treatment strategies that will provide maximum benefit to the individual patient [40] . To Few studies have investigated the potential prognostic utility of FDG PET/CT in prostate cancer. Japanese investigators found that primary prostate tumors with high SUVs had a poorer prognosis than those with low SUVs [41] . Morris et al. showed that an increase of over 33 % in the average maximum SUV measurement from up to five lesions, or the appearance of new lesions, was able to categorize castrate-sensitive metastatic prostate cancer patients treated with antimicrotubule chemotherapy into progressors and nonprogressors [42] . Meirelles et al. evaluated the prognostic utility of bone scintigraphy and FDG PET in 39 patients with castrate-resistant and 12 patients with castratesensitive disease who were followed for at least 5 years or until death [43] . The bone scintigraphy studies were analyzed using the bone scan index [44] . The SUVmax of the most active bone lesion was used as the outcome measure for the FDG PET studies. Survival was inversely associated with bone scan index and SUVmax. The median survival of 28.2 months in patients with bone scan index less than 1.27 was significantly longer than 14.7 months in those patients with bone scan index greater than 1.27. Similarly, median survival of 32.8 months in those with SUVmax less than 6.10 was significantly longer than 14.4 months in those with SUVmax greater than 6.10. SUVmax was determined to be an independent prognostic factor in the multivariate analysis.
We recently found in a prospective investigation of men with castrate-resistant metastatic prostate cancer that the sum of maximum SUV of up to 25 metabolically active lesions on FDG PET/CT (proxy for total burden of metabolically active disease) contributed independent prognostic information on overall survival in a multivariate Cox regression analysis adjusting for standard clinical parameters of age, serum PSA and alkaline phosphatase levels, use of pain medication, prior use of chemotherapy and Gleason score at initial diagnosis [45] (Fig. 3) .
Conclusion
FDG PET/CT is limited in the detection and localization of primary prostate cancer and initial staging of disease since most primary tumors are slow-growing, well-differentiated, multiple, and small, with tumor uptake levels that can overlap with those in normal tissue and BPH. Aggressive poorly differentiated tumors may, however, display high uptake although this is nonspecific and may be seen in benign inflammatory conditions. FDG PET/CT may detect occult metastatic disease in a small proportion of men who present with biochemical recurrence after primary treatment with curative intent. Detection of local recurrence may, however, be limited due to overlap of uptake between recurrent tumor and that in tissue with posttherapy change as well as interference from the nearby bladder urine activity. FDG PET/CT may be most useful in detection of aggressive disease, evaluation of extent and treatment response in metastatic disease and in prognostication in a patient with clinical castrate resistance.
